Phosphate Sandoz 500MG Effervescent Tablets 100 (5 X 20)

PHOSPHATE SANDOZ Effervescent Tablets
Hypercalcaemia associated with such conditions as hyperparathyroidism, multiple myelomatosis and malignancy.
Hypophosphataemia associated with vitamin D resistant rickets and vitamin D resistant hypophosphataemic osteomalacia.
PHOSPHATE SANDOZ Effervescent should be dissolved in 1/3 to 1/2 a tumblerful of water and taken orally.
Dosage should be adjusted to suit the requirements of individual patients. Excessive dosage has been reported to produce hypocalcaemia in isolated cases. Particular care should therefore be taken to ensure appropriate dosage in the elderly.
Adults
Hypercalcaemia: up to 6 tablets daily (adjustment being made according to requirements).
Vitamin D resistant hypophosphateaemic osteomalacia: 4-6 tablets daily.
Children under 5 years
Hypercalcaemia: up to 3 tablets daily (adjustment being made according to requirements).
Vitamin D resistant rickets: 2-3 tablets daily.
In cases of impaired renal function associated with hypercalcaemia and in cases where restricted sodium intake is required, eg. congestive cardiac failure, hypertension or pre-eclamptic toxaemia, the sodium (20.4mmol per tablet) and potassium (3.1mmol per tablet) content of PHOSPHATE SANDOZ should be taken into consideration. In cases of hypercalcaemia associated with impaired renal function and hyperphosphataemia, the main effect of oral phosphate is to bind calcium in the gut and thus reduce calcium absorption.
The effect of oral phosphate on serum phosphate is likely to be minimal, but close monitoring of serum levels is recommended.
Soft tissue calcification and nephrocalcinosis have been reported in isolated cases following intravenous therapy with phosphate.
This is thought to be a function of dosage and rapidity of phosphate administration. While such effects appear less likely to occur with oral phosphates, careful surveillance of patients is recommended, especially if on long term therapy.
Concurrent administra